Year |
Citation |
Score |
2023 |
Tinsley HN, Mathew B, Chen X, Maxuitenko YY, Li N, Lowe WM, Whitt JD, Zhang W, Gary BD, Keeton AB, Grizzle WE, Grubbs CJ, Reynolds RC, Piazza GA. Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats. Cancers. 15. PMID 36765604 DOI: 10.3390/cancers15030646 |
0.716 |
|
2020 |
Abdel-Halim M, Tinsley H, Keeton AB, Weam M, Atta NH, Hammam MA, Hefnawy A, Hartmann RW, Engel M, Piazza GA, Abadi AH. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. Bioorganic Chemistry. 104: 104322. PMID 33142429 DOI: 10.1016/j.bioorg.2020.104322 |
0.636 |
|
2016 |
Abdel-Rahman HM, Abdel-Aziz M, Tinsley HN, Gary BD, Canzoneri JC, Piazza GA. Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors. Archiv Der Pharmazie. 349: 104-11. PMID 26686665 DOI: 10.1002/Ardp.201500363 |
0.646 |
|
2015 |
Windham PF, Tinsley HN. cGMP signaling as a target for the prevention and treatment of breast cancer. Seminars in Cancer Biology. 31: 106-10. PMID 24972142 DOI: 10.1016/J.Semcancer.2014.06.006 |
0.348 |
|
2014 |
Fajardo AM, Piazza GA, Tinsley HN. The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers. 6: 436-58. PMID 24577242 DOI: 10.3390/Cancers6010436 |
0.626 |
|
2013 |
Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH, Moyer MP, Grizzle WE, Chang WC, Clapper ML, Piazza GA. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Molecular Cancer Therapeutics. 12: 1848-59. PMID 23804703 DOI: 10.1158/1535-7163.Mct-13-0048 |
0.758 |
|
2013 |
Abadi AH, Hany MS, Elsharif SA, Eissa AA, Gary BD, Tinsley HN, Piazza GA. Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line. Chemical & Pharmaceutical Bulletin. 61: 405-10. PMID 23546000 DOI: 10.1248/Cpb.C12-00993 |
0.637 |
|
2013 |
Tinsley HN, Grizzle WE, Abadi A, Keeton A, Zhu B, Xi Y, Piazza GA. New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 191: 105-20. PMID 22893202 DOI: 10.1007/978-3-642-30331-9_6 |
0.691 |
|
2013 |
Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Keeton AB, Grizzle WE, Piazza GA. Abstract 3659: Next generation sulindac. Cancer Research. 73: 3659-3659. DOI: 10.1158/1538-7445.Am2013-3659 |
0.752 |
|
2012 |
Tinsley HN, Piazza GA. Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases. Current Colorectal Cancer Reports. 8: 325-330. PMID 23459242 DOI: 10.1007/S11888-012-0142-5 |
0.711 |
|
2012 |
Ahmed NS, Ali AH, El-Nashar SM, Gary BD, Fajardo AM, Tinsley HN, Piazza GA, Negri M, Abadi AH. Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives. European Journal of Medicinal Chemistry. 57: 329-43. PMID 23117589 DOI: 10.1016/J.Ejmech.2012.09.029 |
0.627 |
|
2012 |
Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, Piazza GA. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prevention Research (Philadelphia, Pa.). 5: 822-33. PMID 22556201 DOI: 10.1158/1940-6207.Capr-11-0559 |
0.751 |
|
2012 |
Tinsley HN, Gary BD, Whitt J, Zhang W, Chen X, Keeton AB, Grubbs CJ, Grizzle WE, Piazza GA. Abstract 570: Breast cancer chemopreventive activity of a novel amide derivative of sulindac involves inhibition of PDE5, activation of PKG, and attenuation of Wnt/β-catenin signaling Cancer Research. 72: 570-570. DOI: 10.1158/1538-7445.Am2012-570 |
0.738 |
|
2011 |
Piazza GA, Tinsley HN, Gary BD, Knight MR, Li N, Tiwari KN, Zhang W, Waud WR, Coward LU, Gorman G, Keeton AB, Struck RF, Abadi AH. A novel class of mono-alkylating agents with highly potent and selective tumor cell growth inhibitory activity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13523. PMID 28022698 DOI: 10.1200/Jco.2011.29.15_Suppl.E13523 |
0.708 |
|
2011 |
Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prevention Research (Philadelphia, Pa.). 4: 1275-84. PMID 21505183 DOI: 10.1158/1940-6207.Capr-11-0095 |
0.706 |
|
2011 |
Ahmed NS, Gary BD, Tinsley HN, Piazza GA, Laufer S, Abadi AH. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors. Archiv Der Pharmazie. 344: 149-57. PMID 21384413 DOI: 10.1002/Ardp.201000236 |
0.609 |
|
2011 |
Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM, Abadi AH. Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. Journal of Medicinal Chemistry. 54: 495-509. PMID 21189023 DOI: 10.1021/Jm100842V |
0.675 |
|
2011 |
Whitt JD, Keeton AB, Tinsley HN, Gary BD, Li N, Mathew B, Reynolds RC, Piazza GA. Abstract 837: Novel sulindac derivatives that inhibit colon cancer growth by a COX independent mechanism involving PDE5 inhibition and the suppression of nuclear β-catenin levels Cancer Research. 71: 837-837. DOI: 10.1158/1538-7445.Am2011-837 |
0.683 |
|
2011 |
Sun Y, Keeton AB, Tinsley HN, Butler BL, Binkowski BF, Piazza GA. Abstract 5443: A novel biosensor for monitoring intracellular cGMP in live cells Cancer Research. 71: 5443-5443. DOI: 10.1158/1538-7445.Am2011-5443 |
0.435 |
|
2011 |
Li N, Tinsley H, Whitt J, Gary B, Lu W, Li Y, Keeton A, Piazza G. Abstract 3707: Sulindac sulfide inhibits growth and induces apoptosis of human colon tumor cells by a cGMP-dependent pathway leading to suppression of β-catenin transcription activity Cancer Research. 71: 3707-3707. DOI: 10.1158/1538-7445.Am2011-3707 |
0.637 |
|
2011 |
Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Li N, Gurpinar E, Sun Y, Mathew B, Reynolds RC, Zhang W, Singh R, Coward L, Gorman G, Maxuitenko YY, et al. Abstract 1865: Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac Cancer Research. 71: 1865-1865. DOI: 10.1158/1538-7445.Am2011-1865 |
0.604 |
|
2011 |
Tinsley HN, Keeton AB, Lu W, Li Y, Piazza GA. Abstract 1853: PDE5 suppression selectively induces apoptosis of human breast tumor cells and attenuates Wnt/β-catenin mediated transcription Cancer Research. 71: 1853-1853. DOI: 10.1158/1538-7445.Am2011-1853 |
0.704 |
|
2010 |
Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary BD, Mathew B, Singh R, Grizzle WE, Reynolds RC. NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals (Basel, Switzerland). 3: 1652-1667. PMID 27713322 DOI: 10.3390/Ph3051652 |
0.713 |
|
2010 |
Ahmed NS, Gary BD, Piazza GA, Tinsley HN, Laufer S, Abadi AH. A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 6: 374-87. PMID 21054274 DOI: 10.2174/157340610793563992 |
0.591 |
|
2010 |
Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prevention Research (Philadelphia, Pa.). 3: 1303-13. PMID 20876730 DOI: 10.1158/1940-6207.Capr-10-0030 |
0.728 |
|
2010 |
Abadi AH, Gary BD, Tinsley HN, Piazza GA, Abdel-Halim M. Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. European Journal of Medicinal Chemistry. 45: 1278-86. PMID 20206015 DOI: 10.1016/J.Ejmech.2009.10.046 |
0.624 |
|
2010 |
Abadi AH, Abouel-Ella DA, Lehmann J, Tinsley HN, Gary BD, Piazza GA, Abdel-Fattah MA. Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. European Journal of Medicinal Chemistry. 45: 90-7. PMID 19836860 DOI: 10.1016/J.Ejmech.2009.09.029 |
0.683 |
|
2010 |
Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary B, Mathew B, Singh R, Grizzle WE, Reynolds RC. NSAIDs: Old drugs reveal new anticancer targets Pharmaceuticals. 3: 1652-1667. DOI: 10.3390/ph3051652 |
0.713 |
|
2009 |
Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Molecular Cancer Therapeutics. 8: 3331-40. PMID 19996273 DOI: 10.1158/1535-7163.Mct-09-0758 |
0.692 |
|
2009 |
Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN, Keeton AB, Piazza GA. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittel-Forschung. 59: 415-21. PMID 19813465 DOI: 10.1055/S-0031-1296417 |
0.672 |
|
2009 |
Abadi AH, Ibrahim TM, Abouzid KM, Lehmann J, Tinsley HN, Gary BD, Piazza GA. Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. Bioorganic & Medicinal Chemistry. 17: 5974-82. PMID 19628397 DOI: 10.1016/J.Bmc.2009.06.063 |
0.734 |
|
2009 |
Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prevention Research (Philadelphia, Pa.). 2: 572-80. PMID 19470791 DOI: 10.1158/1940-6207.Capr-09-0001 |
0.729 |
|
2009 |
Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. European Journal of Pharmacology. 602: 8-14. PMID 19026633 DOI: 10.1016/J.Ejphar.2008.10.053 |
0.552 |
|
Show low-probability matches. |